Stem Cell Clinic

Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters

WARREN, N.J., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for management of seizure clusters. The FDA issues a CRL to indicate that the review cycle for an application is complete but the application cannot be approved in its current form.

Read more:
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters

vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients…

Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D

View post:
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients...

BetterLife Provides Update on OTC Trading Activity

VANCOUVER, Sept. 23, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced that it has filed a Form 211 application with the Financial Industry Regulatory Authority (“FINRA”) to request permission to quote and resume trading of its securities on OTC Markets.

See the original post here:
BetterLife Provides Update on OTC Trading Activity

CENTOGENE Reports First Half 2020 Financial Results

The rest is here:
CENTOGENE Reports First Half 2020 Financial Results

Kane Biotech Appoints New Advisor

WINNIPEG, Manitoba, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Company,” “Kane Biotech”) today announced that it has entered into an agreement with Harbor Access LLC (“Harbor Access”), an investor relations advisory firm with offices in Canada and the United States.

Read more here:
Kane Biotech Appoints New Advisor

Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress

ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in over 20 papers and presentations during the EURETINA 2020 Virtual Congress, to be held on October 2-4, 2020.

Go here to see the original:
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress

BioVie Announces Closing of Public Offering of Common Stock

Includes Full Exercise of Underwriters’ Overallotment Option Includes Full Exercise of Underwriters’ Overallotment Option

Read the rest here:
BioVie Announces Closing of Public Offering of Common Stock

VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™

Live webinar on October 1st to feature presentations by 3 KOLs in dermatology Live webinar on October 1st to feature presentations by 3 KOLs in dermatology

Go here to read the rest:
VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™

Unique Enhanced CBD Company – CANNASSIST INTL CORP. Commences Trading on the OTCQB under the Symbol: (CNSC)

FALLBROOK, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- CannAssist International Corporation (OTCQB: CNSC) (“Cannassist” or the “Company”) is pleased to announce the Company is now a new Publicly Traded Company on the OTC Markets Platform - OTCQB Markets Tier. The OTCQB requires a company to be fully reporting under SEC rules and guidelines as a means of accomplishing full transparency for Investors.

Read more:
Unique Enhanced CBD Company - CANNASSIST INTL CORP. Commences Trading on the OTCQB under the Symbol: (CNSC)

Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

BASEL, Switzerland, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program. The program will provide funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S. Myovant will award as many as four grants of up to $50,000 each, for a total of $200,000.

Read the original post:
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids